CIMAvax-EGF: Cuba's Innovative Approach to Lung Cancer Immunotherapy

CIMAvax-EGF represents one of Cuba's most significant medical biotechnology innovations. Developed by the Center of Molecular Immunology (CIM) in Havana, it is a therapeutic vaccine — designed to treat disease rather than prevent it — targeting advanced non-small cell lung cancer.

The vaccine works through a unique mechanism: it stimulates the patient's immune system to produce antibodies against Epidermal Growth Factor (EGF), a protein that tumors rely on to grow and spread. By depriving cancer cells of this signal, tumor growth slows and patient survival is extended. CIMAvax-EGF is typically administered as maintenance therapy following completion of standard first-line treatment.

The vaccine has completed Phase III trials in Cuba and is currently undergoing international clinical trials, including in the United States. It is part of a broader Cuban approach that combines biotechnology innovation with comprehensive patient care, administered under the supervision of experienced oncology teams in specialized clinical facilities with full supportive care and monitoring.